Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?

This a great question and highlights the drug dosing and development process of the use of Pembrolizumab in metastatic Melanoma. In Keynote-002, Pembrolizumab was studied in the does of 2mg/kg and 10mg/kg vs chemotherapy and the CR responses were 2 vs 3% in the Pembrolizumab arms. In Keynote-006, Pe...